Shares of Molecular Templates (MTEM) have risen by roughly 20% since my initial recommendation last year, which highlighted its agreement with Takeda (TKPHF) to develop CD38-targeted engineered toxin bodies (ETBs). On the other hand, shares have fallen by 8% since my June update.
I felt this one merited a revisit after I listened in on management's presentation at Ladenburg Thalmann Healthcare Conference, given that multiple data readouts are expected later this year and Takeda collaboration is progressing nicely as well.
Chart
Figure 1: MTEM daily advanced chart (Source: Finviz)
When looking at